The highest dose outperformed liraglutide, which was notable because liraglutide was, at the time, a leading GLP-1 obesity treatment
while normal dietary intake is considered safe, the effects of high-dose parenteral administration are less well studied
This article provides a detailed comparison of GHK-Cu with related peptides, examining their mechanisms, evidence bases, and practical applications
And eventually, companies started taking their approved GLP-1 diabetes drugs and testing them for weight loss
But the incredible consolidation that's happened among insurers, PBMs, frankly, even the hospitals and pharmacies too, there are either local monopolies in the hospital case or a three-race oligopoly in every other part of the value chain that really is just obfuscated and insulated profits